Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Medtronic
Moodys
Merck
McKesson
McKinsey
Baxter

Last Updated: November 12, 2019

DrugPatentWatch Database Preview

KRINTAFEL Drug Profile

See Plans and Pricing

« Back to Dashboard

When do Krintafel patents expire, and what generic alternatives are available?

Krintafel is a drug marketed by Glaxosmithkline and is included in one NDA.

The generic ingredient in KRINTAFEL is tafenoquine succinate. Two suppliers are listed for this compound. Additional details are available on the tafenoquine succinate profile page.

Drug patent expirations by year for KRINTAFEL
Drug Prices for KRINTAFEL

See drug prices for KRINTAFEL

Synonyms for KRINTAFEL
(+/-)-8-[(4-amino-1-methylbutyl)amino]-2,6-dimethoxy-4-methyl-5-(3-trifluoromethylphenoxy) quinoline
(4-Amino-1-methylbutyl){2,6-dimethoxy-4-methyl-5-[3-(trifluoromethyl)phenoxy](8-quinolyl)}amine
(R)-N3-(2,6-Dimethoxy-4-methyl-5-(3-trifluoromethyl)phenoxy)quinolin-8-yl)pentane-1,4-diamine
(RS)-N(sup 3)-(2,6-Dimethoxy-4-methyl-5-(3-trifluoro-methylphenoxy)quinolin-8-yl)pentane-1,4-diamine
1,4-Pentanediamine, N4-(2,6-dimethoxy-4-methyl-5-(3-(trifluoromethyl)phenoxy)-8-quinolinyl)-
1,4-Pentanediamine, N4-[2,6-dimethoxy-4-methyl-5-[3-(trifluoromethyl)phenoxy]-8-quinolinyl]-
106635-80-7
4-N-[2,6-dimethoxy-4-methyl-5-[3-(trifluoromethyl)phenoxy]quinolin-8-yl]pentane-1,4-diamine
AC1L3GZN
Arakoda
C24H28F3N3O3
CHEBI:141487
CHEMBL298470
CS-0042381
D10490
Etaquine
GTPL9722
HY-111529
LBHLFPGPEGDCJG-UHFFFAOYSA-N
LS-172012
N(4)-(2,6-Dimethoxy-4-methyl-5-((3-trifluoromethyl)phenoxy)-8-quinolinyl)-1,4-pentanediamine
N(4)-{2,6-dimethoxy-4-methyl-5-[3-(trifluoromethyl)phenoxy]quinolin-8-yl}pentane-1,4-diamine
N4-[2,6-dimethoxy-4-methyl-5-[3-(trifluoromethyl)phenoxy]-8-quinolyl]pentane-1,4-diamine
SB-252263
SB-252263-AAB
SB-252263AAB
SB16555
SCHEMBL347388
Tafenoquine
Tafenoquine (USAN)
Tafenoquine [INN:BAN]
Tafenoquine [USAN:INN:BAN]
WR 238605
WR-238605
WR238605

US Patents and Regulatory Information for KRINTAFEL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaxosmithkline KRINTAFEL tafenoquine succinate TABLET;ORAL 210795-001 Jul 20, 2018 RX Yes Yes   Start Trial   Start Trial   Start Trial
Glaxosmithkline KRINTAFEL tafenoquine succinate TABLET;ORAL 210795-001 Jul 20, 2018 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Dow
Johnson and Johnson
Colorcon
Merck
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.